Danziten® (nilotinib)
for Leukemia

Danziten (nilotinib) treats adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), typically when other therapies fail or aren't tolerated. It targets BCR-ABL tyrosine kinase, a protein driving cancer growth, blocking its signaling to stop tumor cell growth and trigger cell death. Danziten doesn’t require fasting, improving patient convenience.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia